Daniella Beckman
2021
In 2021, Daniella Beckman earned a total compensation of $3.2M as Chief Financial Officer at Tango Therapeutics, a 281% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $164,562 |
|---|---|
| Option Awards | $2,630,841 |
| Salary | $377,945 |
| Other | $3,317 |
| Total | $3,176,664 |
Beckman received $2.6M in option awards, accounting for 83% of the total pay in 2021.
Beckman also received $164.6K in non-equity incentive plan, $377.9K in salary and $3.3K in other compensation.
Rankings
In 2021, Daniella Beckman's compensation ranked 4,211th out of 12,406 executives tracked by ExecPay. In other words, Beckman earned more than 66.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,211 out of 12,406 | 66th |
Division Manufacturing | 1,734 out of 5,492 | 68th |
Major group Chemicals And Allied Products | 722 out of 2,368 | 70th |
Industry group Drugs | 644 out of 2,089 | 69th |
Industry Pharmaceutical Preparations | 454 out of 1,536 | 70th |
Source: SEC filing on April 26, 2022.
Beckman's colleagues
We found two more compensation records of executives who worked with Daniella Beckman at Tango Therapeutics in 2021.